FDA Approves Vizz Eye Drops to Improve Near Vision in Adults
By Lori Solomon HealthDay Reporter
TUESDAY, Aug. 5, 2025 -- The U.S. Food and Drug Administration has approved Vizz 1.44 percent (aceclidine ophthalmic solution) for the treatment of presbyopia in adults.
Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the iris sphincter muscle resulting in a pinhole effect, achieving a pupil <2 mm, which extends depth of focus to significantly improve near vision without causing a myopic shift.
The approval was based on data from phase 3 studies: CLARITY 1 and CLARITY 2 evaluated the safety and efficacy of Vizz in 466 participants dosed once daily for 42 days, while CLARITY 3 evaluated 217 participants for long-term safety over six months of once-daily dosing. Across trials, Vizz demonstrated improved near vision within 30 minutes that lasted up to 10 hours. There were no serious treatment-related adverse events observed across all three trials (30,000 treatment days). The most common reported adverse reactions (mostly mild, transient, and self-resolving) included installation site irritation, dim vision, and headache.
"This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and struggling with the inevitable age-related loss of their near vision," Vizz clinical investigator Marc Bloomenstein, O.D., from the Schwartz Laser Eye Care Center in Scottsdale, Arizona, said in a statement. "I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard of care, with a product profile that will meet our patients' needs."
The approval of Vizz was granted to LENZ Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Capsular Tension Ring Implantation Linked to Improved Intraocular Lens Stability
MONDAY, June 23, 2025 -- Capsular tension ring (CTR) implantation is associated with improved stability of the intraocular lens (IOL), according to a review published online June...
Highly Aspherical Lenslet Spectacles Reduce Myopia Progression
THURSDAY, April 10, 2025 -- For children with myopia, wearing spectacles with highly aspherical lenslets (HAL) reduces the rate of myopia progression and axial elongation...
Prevalence, Severity of Pediatric Astigmatism Increased After Pandemic
MONDAY, March 24, 2025 -- The prevalence and severity of refractive astigmatism and corneal astigmatism increased among schoolchildren after the COVID-19 pandemic, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.